Ceftazidime-avibactam: novel antimicrobial combination for the treatment of complicated urinary tract infections.
Ceftazidime-avibactam is a combination of a third-generation cephalosporin and a novel non-beta-lactam beta-lactamase inhibitor. This combination was recently recommended for the treatment of complicated urinary tract infections, including acute pyelonephritis, in adults with limited or no alternative treatment options. The current review is aimed to determine activity, efficacy and safety of ceftazidime-avibactam in the treatment of patients with complicated urinary tract infections.
Clinic & Policlinic for Urology, Pediatric Urology & Andrology, Justus-Liebig University, Giessen, Germany.|Outpatient Department, JSC "Republican Specialized Center of Urology", Tashkent, Uzbekistan.
Jakhongir F
JF
Alidjanov
Clinic & Policlinic for Urology, Pediatric Urology & Andrology, Justus-Liebig University, Giessen, Germany.|Institute for Medical Microbiology, Justus-Liebig University, Giessen, Germany.
Moritz
M
Fritzenwanker
Clinic & Policlinic for Urology, Pediatric Urology & Andrology, Justus-Liebig University, Giessen, Germany.
Ivan
I
Hoffman
Clinic & Policlinic for Urology, Pediatric Urology & Andrology, Justus-Liebig University, Giessen, Germany.
Florian M
FM
Wagenlehner
D000328:Adult; D053961:Azabicyclo Compounds / Q000009:adverse effects / Q000737:chemistry / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use*; D002442:Ceftazidime / Q000009:adverse effects / Q000737:chemistry / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use*; D004338:Drug Combinations; D024901:Drug Resistance, Multiple, Bacterial; D004926:Escherichia coli / Q000187:drug effects; D005260:Female; D006801:Humans; D059413:Intraabdominal Infections / Q000188:drug therapy / Q000382:microbiology; D008297:Male; D008970:Molecular Weight; D011704:Pyelonephritis / Q000188:drug therapy; D014552:Urinary Tract Infections / Q000150:complications* / Q000188:drug therapy* / Q000382:microbiology; D065093:beta-Lactamase Inhibitors / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*
D053961:Azabicyclo Compounds; D004338:Drug Combinations; C000595613:avibactam, ceftazidime drug combination; D065093:beta-Lactamase Inhibitors; C543519:avibactam; D002442:Ceftazidime
antibiotics; antimicrobial agents; avibactam; beta lactamase; beta-lactams; ceftazidime; ceftazidime drug combination; pyelonephritis; urinary tract infections